In this study, participants with type 1 diabetes will take a new medication that has been shown to reduce kidney disease in people living with type 2 diabetes. This medication is called finerenone. No other medication on the market has been shown to reduce kidney disease. Participants will visit with a study nurse about 6 times over 7 months to get study medication and complete blood work.


Currently recruiting participants: No

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 100

Inclusion criteria:

1. Over 18 years of age
2. Living with Type 1 Diabetes
3. Have been diagnosed with chronic kidney disease (CKD)

Exclusion criteria:

1. People with Type 2 Diabetes


Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

Amy Dunlop

Principal investigator:

Ronald Sigal

Clinical trial: